New 36-month data presented showed that hormone receptor-positive postmenopausal breast cancer patients taking an aromatase inhibitor as initial adjuvant therapy were significantly less likely to suffer from bone loss if they received treatment with twice-yearly Zometa® (zoledronic acid, 4mg) adm [click link for full article]
More: continued here